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This study investigated the effects of docosahexaenoic acid (DHA) supplementation on the fatty acid
composition of breast milk and plasma concentrations in lactating women and their infants. Eighty-nine
lactating women 4–6 weeks post-partum received placebo, 200 mg or 400 mg DHA for 6 weeks with
usual diets. Breast milk fatty acids and maternal plasma fatty acids were measured at the beginning and
end of the study and infant plasma at the end of the study. Breast milk and maternal plasma DHA were
signiﬁcantly greater with 200 mg and 400 mg DHA compared with placebo (50% and 123% breast milk
po0.05; 71% and 101% plasma, po0.0001), respectively. Infant plasma omega 6:3 and arachidonic acid
(AA):DHAwere signiﬁcantly greater in the placebo group compared to both supplement groups (67% and
106%; 71% and 116%, respectively, po0.05). DHA supplementation impacts infant fatty acids important
for brain development and breast milk fatty acid composition.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The composition of human breast milk reﬂects the nutritional
status and dietary intake of the lactating mother. Some vitamins
and minerals can be impacted when the mother is under and/or
malnourished [1]. Other nutrients in breast milk, including fatty
acids, are inﬂuenced by maternal nutrition [2]. Linoleic (LA) and α-
linolenic acid (ALA) are omega 6 (n-6) and omega 3 (n-3) fatty
acids, respectively, that are essential in the diet [3,4], and it does
not appear that the secretion of these fatty acids in breast milk is
regulated [5]; therefore, dietary intake by lactating women can
greatly inﬂuence the concentration in breast milk. Docosahexae-
noic acid (DHA) is an n-3 fatty acid that has gained increased
attention over the last 20 years in pregnancy and lactation for its
role in brain development, as it accounts for over 10% of brain fatty
acids [6] and is essential for infant development [7]. Over the ﬁrst
6 months of life, which is the time exclusive breast feeding is
recommended [8], the infant brain doubles in weight, and the
large brain to body weight ratio for infants (0.1) compared with
adults (0.02) [9] may put the infant at greater risk to deﬁcits in
nutrients and energy. Much of the increase in brain weight is
attributed to increased gray matter, corresponding to the forma-
tion of neural synapses [10] which are rich in DHA [11,12]. Neurite
outgrowth, dendritic complexity and neurotransmitter metabo-
lism are also highly reliant on DHA [11]. Although DHA can be
synthesized from its n-3 precursor (ALA) [13], studies have shown
that DHA from the maternal diet is a more efﬁcient source of
neural tissue DHA than an equivalent amount of ALA [14,15], given
that less than 10% ALA is converted to DHA [16].
The amount of DHA in breast milk is inﬂuenced by maternal diet
and parity [17] and the reported level of DHA in breast milk (by
weight) of total fatty acids is 0.3270.22% (mean7standard error)
with a range of 0.06–1.4% [18]. Marine mammals have high amounts
of DHA as it can be synthesized in aquatic phytoplankton and
subsequently transferred up through the aquatic food chain; there-
fore, fatty ﬁsh are a rich dietary source of DHA [19]. Dietary intake of
DHA in many parts of the world is low and has been related to
dietary ﬁsh intake. In a review of worldwide DHA breast milk levels,
4 of the 5 top locations reporting the highest breast milk DHA
concentrations are all coastal or island populations with a diet high
in marine foods. In contrast, those with the lowest reported levels are
either inland or developed countries with low amounts of marine
foods in their diets [18]. Many U.S. women, including those who are
pregnant, do not consume the recommended 8–12 oz (225–350 g) of
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seafood per week [20], resulting in a very low consumption of DHA
during pregnancy and lactation of about 30–70 mg/day [21]. Addi-
tionally, there has been a trend in increased consumption of reﬁned
vegetable oils, such as soybean and canola, as the source of fat in the
diet and subsequent decreased animal fat consumption. This has
resulted in an overall increase in n-6 in the diet as well as decreased
plant sources of n-3, such as ﬂax and walnuts [22], suggesting an
even greater importance for intake of preformed DHA. These dietary
changes, taken together with the overall shift in available dietary
fatty acids over the past several decades has resulted in a signiﬁcant
increase in the ratio of n-6:3 fatty acids to 15–20:1, whereas ratios
closer to 2–4:1 have been recommended for health [23,24].
Although it is well established that DHA supplementation to
lactating women results in increased DHA concentrations, few
studies have examined the impact of this increase on infant fatty
acid parameters. Therefore, as part of a larger multi-site, prospective,
randomized, blinded, placebo-controlled dose response study to
examine DHA, lutein and vitamin E supplementation in lactating
women, the aims of this portion of the study were to determine the
impact of DHA supplementation on fatty acid status of lactating
women and their infants. The objectives in this dose response model
were to (1) examine the impact of DHA supplementation on infant
fatty acids (2) and conﬁrm the responsivity of DHA supplementation
to lactating women.
2. Subjects and methods
2.1. Subjects and study design
Eighty-nine (89) U.S. mothers Z18 years who had delivered full-
term singleton infants that were 4–6 weeks post-partum, had been
continuously successfully lactating, and planned to continue breast-
feeding for at least 6 weeks were enrolled as part of an umbrella
study of lutein, DHA and vitamin E supplementation previously
described [25]. Seven were excluded for reasons documented in
Fig. 1. Only fatty acid data are currently presented. Subjects (n¼9
placebo, n¼6 low dose and n¼6 high dose) consuming a supple-
ment with DHA/ﬁsh oil participated in a 10-day washout prior to
starting the study and all subjects were asked to discontinue these
supplements during the study. Subjects were randomly assigned to
1 of 3 groups and were asked to consume 2 study capsules daily in
the morning with food for 6 weeks; no groups were given other
dietary advice. The 3 groups were (1) 2 placebo capsules (placebo),
(2) 1 placeboþ1 experimental capsule containing 200 mg DHA
(low dose) or (3) 2 capsules containing 400 mg DHA (high dose).
The placebo capsules were identical in appearance to the experi-
mental capsules and did not contain DHA (Table 1).
Subjects provided a baseline breast milk and blood sample
prior to starting the supplement, weekly breast milk samples and
an optional blood sample and infant blood sample at the end of
study for determination of fatty acids as described below in
Section 2.3. Infant birth weight and length were collected at the
end of the study. For those infants providing a blood sample, an
infant food record was also collected. All subjects completed a food
frequency questionnaire (FFQ) modiﬁed from a previously pub-
lished version [26] and completed a weekly 3 day food record as
previously described [25]. This study was approved by the Coper-
nicus Group Institutional Review Board. Written informed consent
was obtained from all subjects before enrollment.
2.2. Breast milk and blood sample collections
Subjects were instructed on breast milk collection as previously
described [25]. Brieﬂy, approximately 20 ml mid-milk sample was
collected and it was recommended to collect milk at the same time
of the day for each visit in the afternoon. Samples were either
frozen immediately or kept under refrigerated temperatures for
r12 h prior to freezing. Venous blood samples (6 ml mother
and 4 ml infant) were collected in Na heparin vacuum-tubes.
The plasma layer was transferred into Eppendorf tubes and stored
at 20 1C for not more than 6 weeks until the analysis was
performed as described below.
2.3. Fatty acid analysis
All samples were stored at 20 1C for no more than 4–6 weeks,
and shipped to the analytical laboratory (Craft Technologies, Inc.,
Wilson, NC, USA). Fatty acids were analyzed as previously described
[27]. Lipids and fatty acids were extracted from breast milk by organic
solvents and lipids extracts were hydrolyzed and methylated to fatty
acid methyl esters (FAMEs) using BF3 in methanol. Heparinized
plasma samples had an internal standard (C17:0 or C23:0 in chloro-
form) added and lipids were extracted twice in 2 ml of chloroform:
methanol (1:1 v/v) by a vortex-mixing for 1 min. After centrifugation,
the chloroform extract was combined, taken to dryness in a centri-
fugal evaporator and hydrolyzed and methylated to FAMEs using BF3
in methanol. Breast milk and plasma sample FAMEs were extracted
twice with n-hexane and quantitatively measured by a capillary gas
chromatography (GC). Saturated and monounsaturated fats were
calculated as the sum of respective fatty acids. Prepared FAMEs were
analyzed by GC instrumentation equipped with a fused silica column
coated with bonded polyglycol liquid phase, oxygen scrubber in
carrier gas line and ﬂame ionization detector.
2.4. Sample size and statistical analysis
The sample size was obtained from the software package nQuery
Advisor 5.0 (Statistical Solutions Ltd., Cork, Ireland). The primary
outcome of the umbrella study was breast milk lutein; therefore, the
sample size was calculated on this parameter [25] and the sample size
achieved in this study allowed for an observed power of 92% for DHA,
conﬁrming that there was adequate power to detect a difference in
breast milk DHA. Analysis of variance was used in baseline compar-
isons of continuous variables, while the Cochran–Mantel–Haenszel
test statistics were used in baseline comparisons of categorical vari-
ables. Fatty acids were compared among treatment groups using ana-
lysis of variance techniques. Relationships among treatment groups
were explored using linear regression. Comparisons between paired
data were analyzed using t-tests and correlations, as appropriate. If
the residuals were not from a normal distribution, a transformation of
the data (e.g. natural log) may have been used in order to improve
the model ﬁt. SASs (Cary, NC) Version 9.2 was used to perform the
statistical analyses.
3. Results
3.1. Subject characteristics
Of the 89 subjects enrolled in the study, 82 provided data for the
analysis. Five subjects were lost to follow-up and did not continue
with study visits (Fig. 1). One subject was found not to be eligible
after study completion and one subject never consumed the study
supplement. All were similar in age and body mass index (BMI) and
the signiﬁcant majority of the subjects were white with an average
age of 2970.5 and pre-pregnancy BMI of 2470.33. The average self-
reported intake of study supplements was 95% (93–97%) and was not
different among study groups. There was no reported difference in
dietary intake of ﬁsh or DHA fortiﬁed foods in the month prior to
start of the study as assessed by FFQ. No signiﬁcant differences in
dietary intake of DHA were reported throughout the study as
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determined by self-reported 3 day food records (60.02711.25
placebo, 78.39724.05 low dose and 51.7179.14 high dose mg/day,
p¼0.64). The characteristics of the infants are summarized else-
where [25]; there was no difference among the groups in feeding the
infants received. There was no difference in adverse events or serious
adverse events among groups in the mothers or infants and none
were related to the study intervention.
3.2. Characteristics of fatty acids in breast milk and plasma
At the beginning of the study there were no differences in
absolute (Table 2) or percent total (data not shown) fatty acids in
breast milk among treatment groups; however, there were differ-
ences in several plasma fatty acids among the groups (Table 3).
Baseline values were used as covariates in the model accounting
for these differences when determining the impact of supplemen-
tation. For all subjects, polyunsaturated fatty acids (PUFAs) was the
most abundant in maternal plasma while saturated fatty acids
were the most abundant in breast milk at baseline (Fig. 2A). The
individual fatty acid with the highest concentration was LA in
maternal and infant plasma; oleic acid had the highest concentra-
tion in breast milk with LA third after palmitic acid (Fig. 2B). Infant
plasma (placebo group only) more closely matched the fatty acid
distribution of maternal plasma compared with breast milk with
the highest concentration being PUFA and LA (Fig. 2A and B). Also
the concentrations of infant plasma n-3 and n-6 fatty acids were
more similar to maternal plasma compared with breast milk, and
plasma concentrations were greater than breast milk (Fig. 2A).
There was a signiﬁcant correlation between breast milk and
maternal plasma DHA, ALA and eicosapentaenoic acid (EPA) at
baseline (r¼0.41, p¼0.0002 DHA; r¼0.22, p¼0.05 ALA; r¼0.24,
p¼0.03 EPA, respectively) and the strength of these correlations
increased with supplementation (data not shown). In addition, γ-
linolenic acid (GLA) demonstrated a signiﬁcant correlation after
supplementation (r¼0.23 and p¼0.04).
3.3. Breast milk fatty acids
After 6 weeks of supplementation with the low or high dose of
DHA, absolute breast milk DHA was signiﬁcantly greater compared
with placebo (Table 2), which was also signiﬁcant when represented
Assessed for eligibility 
(n=234)
Excluded  (n=145)
• Not meeting inclusion 
criteria (n=94)
• Declined to participate 
(n=49)
• Other reasons (n=2)
R d i d ( 89)
Allocated to placebo (n=29)
• Received allocated 
i t ti ( 29)
Allocated to low dose (200mg/d 
DHA) (n=30)
R i d ll d
an om ze n=
Allocated to high dose (400mg/d 
DHA) (n=30)
R i d ll d i in erven on n=
• Did not receive allocated 
intervention (n=0)
• ece ve  a ocate
intervention (n=30)
• Did not receive allocated 
intervention n=0)
• ece ve  a ocate ntervent on 
(n=29)
• Did not receive allocated 
intervention (n=1)
• Subject was found not to be 
eligible after randomization 
but prior to intervention
Lost to follow-up (n=1)
• Subject did not continue with 
visits
Discontinued intervention (n=1)
• Depression 
Lost to follow-up (n=1)
• Subject did not continue with 
visits
Lost to follow-up (n=2)
• Subject did not continue 
with visits (n=2)
Analyzed  (n=27)
Excluded from analysis (n=0)
Analyzed  (n=29)
Excluded from analysis (n=0)
Analyzed  (n=26)
Excluded from analysis (n=1)
• Subject was found to not be
eligible after exit
Fig. 1. Consolidated Standards of Reporting Trials (CONSORT) ﬂow diagram.
Table 1
Composition of study supplements.
Nutrient Placebo Experimental
Calories 5 5
Palmitic acid (16:0), mg 59.9 27.7
Stearic acid (18:0), mg 24.9 9.11
Oleic acid (18:1n9), mg 123.6 13.3
LA (18:2n-6), mg 305.3 25.8
EPA (20:5n-3), mg 0 39.2
DHA (22:6n-3), mg 0 207
Lutein, mg 0 6
D-α-tocopherol, IU 0 30
DL-α-tocopheryl acetate, IU 50.6 0
LA, linoleic acid; EPA, eicosapentaenoic acid; DHA docosahexaenoic acid.
Placebo group consumed 2 placebo capsules, low dose consumed 1 placebo capsule
and 1 experimental capsule and high dose consumed 2 experimental capsules.
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as percent total (0.3570.02 and 0.4570.02 vs. 0.1870.02, po
0.0001). There was also a 29% increase in the high dose as compared
to low dose groups as a percent total (po0.0005) and a trend
towards an increase as an absolute concentration (p¼0.06), however
this did not reach signiﬁcance (Table 2). The high dose group
demonstrated a 154% increase over time (baseline to 6 weeks) in
breast milk DHA (Table 2) and there was a signiﬁcant, positive linear
relationship among the three groups (R2¼0.20). The placebo group
had a 40% increase in each of the following: LA, PUFA and n-6 fatty
acids compared with the low dose group after 6 weeks of supple-
mentation. After 6 weeks of supplementation, the ratio of total n-6:3
was 20% greater in the placebo group compared with both treat-
ment groups; there was no difference between treatment groups. In
the low and high dose groups, the total n-6:3 was reduced by 10%
and 19%, respectively, after 6 weeks of supplementation. Given there
was no difference in the ratio of LA:ALA (data not shown) among the
groups, and the ratio of AA:DHA was 84% and 158% greater in the
placebo group compared with both treatment groups, respectively,
the change in the total n-6:3 appears to be driven speciﬁcally by the
changes in DHA. Additionally, the low dose group AA:DHA ratio was
40% greater than the high dose group at the end of the study.
Eicosapentaenoic acid increased 35% over time in the high dose
group, but was not different among treatment groups. Several fatty
acids decreased over time in the low dose group (GLA, AA, PUFA,
saturated fatty acids, n-6, total identiﬁed fatty acids and n-6:3), but
no changes were seen in the other groups (Table 2).
3.4. Plasma fatty acids
After 6 weeks of supplementation with low or high dose of DHA,
maternal plasma DHA increased by 71% and 101%, respectively
(Table 3), compared with placebo which was also signiﬁcantly repre-
sented as a percent total (1.9270.09 and 2.4570.11 vs. 1.1370.09,
po0.0001). The high dose supplement was 18% greater than low dose
Table 2
Fatty acid composition of breast milk.
Fatty acid (mg/dl) Placebo (n¼27) Low dose (n¼29) High dose (n¼26)
Baseline 6 weeks Baseline 6 weeks Baseline 6 weeks
Palmitic acid (16:0) 621.50747.14 675.41751.95 665.27757.55 547.93742.53 574.19745.63 616.67768.53
Oleic acid (18:1n-9) 981.80767.76 1032.83782.26 936.37789.13 785.19766.63 895.96773.45 882.25795.26
LA (18:2n-6) 557.85748.05 609.68749.35a 522.87748.23 423.15737.34b 485.49743.65 467.30748.33a,b
ALA (18:3n-3) 42.2674.09 45.0974.12 41.8374.67 34.9173.55 34.2772.83 35.0973.96
GLA (18:3n-6) 3.9070.37 4.3870.50 4.4870.39 3.3570.32* 3.7370.36 3.0570.40
AA (20:4n-6) 14.5171.03 14.8371.23 16.1071.49 11.5870.91* 13.6271.06 12.1271.23
EPA (20:5n-3) 1.5570.10 1.6170.20 1.8470.21 1.9070.23 1.5370.14 2.0670.21*
DPA (22:5n-3) 3.7070.25 3.9970.38 3.9970.42 3.4370.34 3.3070.30 3.5870.41
DHA (22:6n-3) 5.7870.50 5.8770.73a 6.9870.94 8.8371.03b 5.1470.51 13.0871.69b,*
Monounsaturated 1141.99775.86 1192.56792.79 1100.177103.00 906.55776.15 1041.39785.26 1015.967108.00
Polyunsaturated 668.83755.51 721.97758.52a 638.86758.70 513.67744.53b,* 583.55749.51 566.53758.24a,b
Saturated 1207.80784.08 1329.347114.29 1300.747114.08 1042.91778.83* 1102.16788.49 1259.827141.56
Total n-3 61.4574.96 64.2175.64 63.0476.45 55.1675.14 51.5074.05 60.6376.66
Total n-6 605.53750.76 655.80753.22a 573.66752.28 456.81739.54b,* 530.12745.70 503.78751.76a,b
Total fatty acids 3018.617196.52 3243.877256.89 3039.767262.84 2463.127188.75* 2727.107215.13 2842.327300.49
Total n-6:3 9.9570.24 10.5370.33a 9.3770.28 8.4970.26b,* 10.3370.40 8.6770.34b,*
AA:DHA 2.6470.11 2.8170.12a 4.0271.51 1.5370.13b 2.8170.31 1.0970.10c,*
LA, linoleic acid; ALA, α-linolenic acid; GLA, γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid.
All values are means7SEMs mg/dl. Values with different letters indicate signiﬁcant difference by ANCOVA after log transformation among treatment groups at a visit
(po0.05) and symbols (*) indicate signiﬁcant difference by t test between visits within a treatment group (po0.05).
Table 3
Fatty acid composition of maternal plasma.
Fatty acid (mg/dl) Placebo (n¼27) Low dose (n¼29) High dose (n¼26)
Baseline 6 weeks Baseline 6 weeks Baseline 6 weeks
Palmitic acid (16:0) 70.9575.68 62.4274.25x,* 59.7272.31 61.5673.31y 64.7874.08 56.4572.95x,*
Oleic acid (18:1n-9) 59.1875.76a 53.1175.52x 44.4472.36b 48.6773.11y 52.0174.82a,b 43.5573.29x,*
LA (18:2n-6) 92.4675.05a 88.9573.99 75.4372.98b 79.8373.03 84.4073.47a 78.2473.38*
ALA (18:3n-3) 2.7470.29 2.3570.22* 1.9870.15 2.1070.18 2.2270.19 1.9570.18
GLA (18:3n-6) 1.3370.17 1.2170.10 1.4070.15 1.2570.09 1.1570.12 1.0670.10
AA (20:4n-6) 20.4271.18 19.4170.81x 20.4770.84 20.0470.76x 20.8470.72 17.2970.70y,*
EPA (20:5n-3) 1.5470.11 1.2670.10x,* 1.8670.10 1.8670.15y 1.6470.17 1.7970.12y
DPA (22:5n-3) 1.3270.09 1.2670.07x 1.2770.07 1.1970.06x 1.2970.07 1.0270.06y,*
DHA (22:6n-3) 3.8270.26 2.9870.17x,* 4.1370.19 5.0970.27y,* 3.5070.16 5.9970.32z,*
Monounsaturated 72.4177.15a 64.4076.37 55.2073.00b 59.3473.67 63.7875.82a,b 52.9174.11*
Polyunsaturated 130.8076.93a 123.7974.90 113.3474.08b 117.4873.93 121.8174.28a,b 112.8374.02*
Saturated 101.2777.53 90.7075.64* 86.8273.25 90.4874.57 93.6675.78 84.0574.39*
Total n-3 9.8670.65 8.3070.42x,* 9.6770.34 10.6970.53y,* 9.0570.45 11.1370.54y,*
Total n-6 120.7176.36a 115.2474.64 103.4573.82b 106.5373.52 112.5274.05a 101.4473.75*
Total fatty acids 304.48721.23a 278.89716.34 255.3779.49b 267.30711.34 279.25715.24a,b 249.79711.46*
Total n-6:3 12.7070.48a 14.4170.63x,* 10.8270.32b 10.3570.36y 12.9370.62a 9.3870.43z,*
AA:DHA 5.5870.26a,b 6.8270.31x,* 5.1470.23a 4.2370.26y,* 6.1670.26b 3.0370.19z,*
LA, linoleic acid; ALA, α-linolenic acid; GLA, γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid.
All values are means77SEMs mg/dl. Values with different letters indicate signiﬁcant difference by ANCOVA after log transformation among treatment groups at baseline
(a–c) and 6 weeks (x–z) (po0.05) and symbols (*) indicate signiﬁcant difference by t test between baseline and 6 weeks within a treatment group (po0.05).
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(Table 3), and signiﬁcant when expressed as percent total. Both
supplement groups demonstrated a signiﬁcant increase in plasma
DHA over time, whereas the placebo group had a signiﬁcant decrease
in plasma DHA over time (Table 3). There was a signiﬁcant, positive
linear relationship among the three groups (R2¼0.56). The placebo
group had the highest n-6:3 and AA:DHA ratios, and increasing the
amount of DHA in the supplement resulted in lower ratios (Table 3).
There was no difference in LA:ALA among the groups (data not
shown), suggesting that the changes in n-6:3 are driven by the
changes in DHA. Over time, the ratio of AA:DHA decreased in both
the low and high dose groups, the ratio of n-6:3 decreased only in the
high dose group and both ratios increased in the placebo group
(Table 3). Several other fatty acids changed after 6 weeks of supple-
mentation in maternal plasma. Of note, EPA and n-3 fatty acids were
signiﬁcantly increased in the low and high dose groups compared
with placebo and docosapentaenoic acid (DPA) was signiﬁcantly
greater in the placebo and low dose groups compared with the high
dose group. Infant plasma n-6:3 and AA:DHA ratios were higher for
those whose mothers received the placebo (n¼11) compared with the
low (n¼11) and high (n¼5) dose supplement groups (Supplemental
Table 1); there were no differences in LA:ALA (data not shown). Infants
whose mothers received the placebo had higher plasma palmitic acid,
oleic acid, LA, ALA, DPA and n-6 compared with the high dose group,
of which oleic acid, ALA and DPAwere also greater as compared to the
low dose group.
4. Discussion and conclusions
4.1. Discussion
One of the primary objectives of this supplementation study
was to determine the impact of maternal DHA supplementation on
infant fatty acids, and due to limitations of sample size there was
no conclusive evidence that DHA in infants was directly impacted.
Our data demonstrated a signiﬁcant increase in infant DHA as
percent total fatty acids for high dose compared with placebo.
There was a trend towards a decrease in total fatty acids in the
infants whose mothers received the low dose (p¼0.088) or high
dose (p¼0.051) of DHA compared with placebo. Therefore, given
the high dose group had almost half the total fatty acids as the
placebo group, it is the opinion of these investigators that the
increase as percent total was not a true representation of the data.
Nonetheless, these data are the ﬁrst to demonstrate that the
infants from both the low and high dose supplemented mothers
reported a 40% and 51%, respectively, lower n-6:3 fatty acid ratio,
as compared to infants from the placebo mothers. A lower n-6:3
ratio diet fed to rodents during brain development has been
shown to result in the greatest relative percentage DHA accumula-
tion in three critical regions of the brain [28], and it has been
suggested that an imbalance in n-6:3 early in life may lead to
irreversible changes in the hypothalamus [29]. Additionally, an
increased amount of n-3 has been shown to beneﬁt learning and
memory [30], in addition to overcoming deﬁcits induced by
neurotoxins in a rodent model [31]. A ratio of 4:1 has been shown
to be the most effective in improving neuro-cognitive measures
[30] and is recommended as optimal for healthy adults [32].
Infants from mothers on the high dose achieved a ratio closest
to this recommendation (5.44:1) among all the groups. A recent
study has demonstrated that maternal DHA supplementation can
confer a long-term beneﬁt on neurodevelopment 5 years later
[33]. Only one other study has looked at infant blood concentra-
tions with maternal DHA supplementation and demonstrated that
0.35–1.13 g/day DHA given to lactating women for 12 weeks
increased infant plasma phospholipid DHA as percent total [34].
Several studies over a decade ago examined the impact of DHA
supplementation in lactating women [13,35–39] from numerous
different populations. Baseline breast milk DHA (0.2170.01% total
fatty acids) in this cohort was less than the worldwide mean of
0.3270.22% [18]. Our data demonstrate that in lactating womenwith
relatively low ﬁsh intake, which is the primary dietary source of DHA,
supplementation signiﬁcantly increased breast milk and circulating
DHA in mothers as well as decreased the ratio of n-6:3 in infants. Our
results in breast milk are in agreement with several others [13,35–
37,39] that used similar doses of DHA during several different time
periods of supplementation. Additionally, a recent analysis [40] of a
previous dose response study [34] provides an equation relating
maternal intake and breast milk DHA output (r2¼0.998), which is in
agreement with the current data (r2¼0.995). Both doses of DHA
increased breast milk DHA compared with placebo; however, this was
not the case in a previous dose response study, which only showed
increases at 400 mg or more of DHA [38]. Women in the previous
study started supplementation 5 days post-partum for 12 weeks and
it is known that breast milk DHA decreases over the ﬁrst 6–16 weeks
post-partum [41]; therefore, it is possible in the current study that
breast milk DHA had stabilized at 6 weeks enough for a 200mg dose
to have an impact.
Baseline plasma DHA in the current study is similar to previous
studies with a collection about the same period post-partum, 4–8
weeks [39] and greater than others [42] with very early post-
partum collection (3 days post-partum) and the early changes in
fatty acids proﬁles after delivery may account for these differences.
There was no difference among groups in baseline ﬁsh intake as
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Fig. 2. Comparison of fatty acids in maternal plasma and breast milk and infant
plasma. Maternal data is all subjects reported at baseline and infant plasma placebo
group reported at study completion. Values are means and represented as
percentage of fatty acids in the tissue. DHA, docosahexaenoic acid; DPA, docosa-
pentaenoic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; GLA, γ-linolenic
acid; ALA, α-linolenic acid; LA, linoleic acid.
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assessed by FFQ or DHA intake over the course of the study
determined by 3 day food records, supporting that the increase
was due to the supplement. Both doses of supplement increased
plasma DHA which is consistent with previous research [35,36] and
demonstrated a signiﬁcant difference between the two doses,
which is similar to Hawkes et al. [35] that supplemented with
300 and 600 mg of DHA for 4 weeks. Another study with increasing
doses only showed a signiﬁcant difference in plasma with a much
higher dose (1021 mg/day DHA as cod liver oil) but demonstrated
increase in breast milk DHA at all doses [39]. It is likely that the
shorter supplementation (14 days) time or DHA delivery as cod liver
oil which were not able to impact plasma phospholipids levels.
Several other PUFA responded to DHA supplementation. Eico-
sapentaenoic acid was increased over time in breast milk with the
high dose of DHA. Additionally in maternal plasma both doses had
signiﬁcantly higher EPA after 6 weeks of supplementation com-
pared with placebo. Others have reported increases in breast milk
[35,39] and plasma [35] EPA with a DHA supplement. There is
inherent EPA that is present in many supplements and may be the
reason for increased levels. In both the low and high dose groups,
n-3 fatty acids increased in plasma and n-6 decreased slightly in
breast milk resulting in a decrease in the ratio of n-6:3 in both
tissues, which is similar to some [37] but not others [39]. A lower
n-6:3 ratio is considered to provide possible health beneﬁts [23].
Docosapentaenoic acid, an elongated metabolite of EPA and an
intermediary product between EPA and DHA, decreased in mater-
nal plasma with DHA supplementation which has been seen in
similar studies [38] with longer periods of supplementation, but
not in others with short supplementation periods [37,39].
4.2. Conclusions
Numerous consensus statements recommend at least 200 mg per
day of DHA for pregnant and lactating women [3,4] and data from
our study and others [13,39] demonstrate that many lactating
women are only receiving around 25% of this recommended amount.
The breast milk DHA concentration was 4–6 times lower in the
current baseline sample compared with those with the highest ﬁsh
intake [18,43] and 1.5 times lower than the worldwide mean [18].
Limitations of this study include the plasma phospholipids were not
analyzed due to the secondary analysis from a multi-nutrient
supplementation trial and the enrollment time post-partum resulted
in a shorter washout. Nonetheless, supplementation was able to
achieve a concentration similar (low dose) or slightly higher (high
dose) than the worldwide mean, suggesting that supplementation
may be necessary for those with low dietary intake. Additionally, the
current study demonstrated that maternal supplementation impacts
fatty acids in infants that have been shown important for brain
development. Results are inconclusive on the long-term cognitive
impact of DHA supplementation during pregnancy on the offspring
[44,45]; however, the importance of adequate PUFA in the infant diet
for normal growth and development is well established [46]. Taken
together, this study demonstrates that in a population with low
dietary intake of DHA, supplementation results in an increase in
breast milk and maternal DHA at levels that would reﬂect adequate
dietary intake and beneﬁcially impact fatty acid ratios in infants
important for brain development.
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